JP7532672B2 - ＦｉｍＨ変異体、それを含む組成物、及びその使用 - Google Patents

ＦｉｍＨ変異体、それを含む組成物、及びその使用 Download PDF

Info

Publication number
JP7532672B2
JP7532672B2 JP2023541784A JP2023541784A JP7532672B2 JP 7532672 B2 JP7532672 B2 JP 7532672B2 JP 2023541784 A JP2023541784 A JP 2023541784A JP 2023541784 A JP2023541784 A JP 2023541784A JP 7532672 B2 JP7532672 B2 JP 7532672B2
Authority
JP
Japan
Prior art keywords
fimh
polypeptide
seq
amino acid
f71mut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023541784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502854A (ja
Inventor
グリープストラ，ヤン
ウェールデンブルグ，エヴリン，マーリーン
ゲウルトセン，イェルーン
フェイ，ケレン，クリスティーナ
ファイツマ，ロウリス，ヤコブ
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2024502854A publication Critical patent/JP2024502854A/ja
Priority to JP2024068916A priority Critical patent/JP2024109576A/ja
Application granted granted Critical
Publication of JP7532672B2 publication Critical patent/JP7532672B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023541784A 2021-01-12 2022-01-11 ＦｉｍＨ変異体、それを含む組成物、及びその使用 Active JP7532672B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024068916A JP2024109576A (ja) 2021-01-12 2024-04-22 ＦｉｍＨ変異体、それを含む組成物、及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21151126 2021-01-12
EP21151126.6 2021-01-12
PCT/IB2022/050166 WO2022153166A1 (en) 2021-01-12 2022-01-11 Fimh mutants, compositions therewith and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024068916A Division JP2024109576A (ja) 2021-01-12 2024-04-22 ＦｉｍＨ変異体、それを含む組成物、及びその使用

Publications (2)

Publication Number Publication Date
JP2024502854A JP2024502854A (ja) 2024-01-23
JP7532672B2 true JP7532672B2 (ja) 2024-08-13

Family

ID=74175646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023541784A Active JP7532672B2 (ja) 2021-01-12 2022-01-11 ＦｉｍＨ変異体、それを含む組成物、及びその使用
JP2024068916A Pending JP2024109576A (ja) 2021-01-12 2024-04-22 ＦｉｍＨ変異体、それを含む組成物、及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024068916A Pending JP2024109576A (ja) 2021-01-12 2024-04-22 ＦｉｍＨ変異体、それを含む組成物、及びその使用

Country Status (12)

Country Link
US (3) US11725028B2 (https=)
EP (1) EP4277921A1 (https=)
JP (2) JP7532672B2 (https=)
KR (2) KR20250007029A (https=)
CN (1) CN116888140A (https=)
AR (1) AR124604A1 (https=)
AU (1) AU2022207740B2 (https=)
CA (1) CA3207841A1 (https=)
IL (1) IL303954B2 (https=)
MX (1) MX2023008251A (https=)
TW (1) TW202241929A (https=)
WO (1) WO2022153166A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
PE20241621A1 (es) * 2021-12-17 2024-08-07 Pfizer Composiciones de polinucleotidos y sus usos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102974A2 (en) 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6737063B2 (en) 2000-07-07 2004-05-18 Medimmune, Inc. FimH adhesin proteins and methods of use
WO2016183501A1 (en) 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
JP2003505030A (ja) * 1999-07-15 2003-02-12 メディミューン，インコーポレーテッド ＦｉｍＨアドヘジンベイストワクチン
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
EP1313502A4 (en) * 2000-08-18 2005-10-19 Medimmune Inc ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
EP1874342B1 (en) 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
CA3074593A1 (en) * 2017-09-08 2019-03-14 The University Of Bristol Protein delivery to membranes
US20190275134A1 (en) * 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US20240027467A1 (en) * 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737063B2 (en) 2000-07-07 2004-05-18 Medimmune, Inc. FimH adhesin proteins and methods of use
WO2002102974A2 (en) 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
WO2016183501A1 (en) 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Folia Microbiologica，2019年，Vol.64, No.4，p.587-600
JOURNAL OF BIOLOGICAL CHEMISTRY，2013年，Vol.288, No.33，p.24128-24139
Proteins，2019年，Vol.88, No.4，p.593-603

Also Published As

Publication number Publication date
US11725028B2 (en) 2023-08-15
CN116888140A (zh) 2023-10-13
MX2023008251A (es) 2023-07-26
TW202241929A (zh) 2022-11-01
US20220220159A1 (en) 2022-07-14
JP2024109576A (ja) 2024-08-14
IL303954B1 (en) 2024-12-01
AR124604A1 (es) 2023-04-12
AU2022207740B2 (en) 2024-06-06
US20230406890A1 (en) 2023-12-21
US12297238B2 (en) 2025-05-13
KR20250007029A (ko) 2025-01-13
IL303954A (en) 2023-08-01
IL303954B2 (en) 2025-04-01
JP2024502854A (ja) 2024-01-23
CA3207841A1 (en) 2022-07-21
KR102746713B1 (ko) 2024-12-24
KR20230125842A (ko) 2023-08-29
US20250289854A1 (en) 2025-09-18
AU2022207740A1 (en) 2023-06-29
AU2022207740A9 (en) 2024-09-05
EP4277921A1 (en) 2023-11-22
WO2022153166A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7485771B2 (ja) ＦｉｍＨ変異体、その組成物、及びその使用
US12297238B2 (en) FimH mutants, compositions therewith and use thereof
EA050404B1 (ru) Мутанты fimh, композиции с ними и их применение
HK40118175A (en) Fimh mutant, compositions therewith and use thereof
EA047213B1 (ru) Мутантная форма fimh, композиции на ее основе и их применение
HK40084704A (en) Fimh mutant, compositions therewith and use thereof
HK40084704B (en) Fimh mutant, compositions therewith and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231206

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7532672

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150